Want to see SE:CLBIO full AI Analyst Report?
Corline Biomedical AB (CLBIO) Stock Statistics & Valuation Metrics
Total Valuation
Corline Biomedical AB has a market cap or net worth of SEK 371.09M. The enterprise value is SEK 436.10M.
- Market Cap
- SEK 371.09M
- Enterprise Value
- SEK 436.10M
Share Statistics
Corline Biomedical AB has 26,133,118 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 26,133,118
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Corline Biomedical AB’s return on equity (ROE) is -0.16 and return on invested capital (ROIC) is -15.15%.
- Return on Equity (ROE)
- -0.16
- Return on Assets (ROA)
- -0.15
- Return on Invested Capital (ROIC)
- -15.15%
- Return on Capital Employed (ROCE)
- -0.15
- Revenue Per Employee
- 546.50K
- Profits Per Employee
- -1.05M
- Employee Count
- 14
- Asset Turnover
- 0.08
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Corline Biomedical AB is -28.83. Corline Biomedical AB’s PEG ratio is -0.42.
- PE Ratio
- -28.83
- PS Ratio
- 29.96
- PB Ratio
- 3.75
- Price to FCF
- -24.99
- Price to Operating Cash Flow
- -25.69
- PEG Ratio
- -0.42
Income Statement
In the last 12 months, Corline Biomedical AB had revenue of 7.65M and earned -14.71M in profits. Earnings per share was -0.59.
- Revenue
- 7.65M
- Gross Profit
- -14.21M
- Operating Income
- -14.21M
- Pretax Income
- -14.71M
- Net Income
- -14.71M
- EBITDA
- -14.12M
- Earnings Per Share (EPS)
- -0.59
Cash Flow
In the last 12 months, operating cash flow was -14.44M and capital expenditures -709,000, giving a free cash flow of -14.85M billion.
- Operating Cash Flow
- -14.44M
- Free Cash Flow
- -14.85M
- Free Cash Flow per Share
- -0.57
Dividends & Yields
Corline Biomedical AB pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -4.00%
- Earnings Yield
- -3.32%
Stock Price Statistics
- Beta
- 0.43
- 52-Week Price Change
- -28.64%
- 50-Day Moving Average
- 14.98
- 200-Day Moving Average
- 16.45
- Relative Strength Index (RSI)
- 48.43
- Average Volume (3m)
- 9,580
Important Dates
Corline Biomedical AB upcoming earnings date is Nov 19, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 21, 2026
- Next Earnings Date
- Nov 19, 2026
- Ex-Dividend Date
- ―
Financial Position
Corline Biomedical AB as a current ratio of 4.98, with Debt / Equity ratio of 0.00%
- Current Ratio
- 4.98
- Quick Ratio
- 4.98
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.46
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Corline Biomedical AB has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Corline Biomedical AB EV to EBITDA ratio is -27.65, with an EV/FCF ratio of -22.76.
- EV to Sales
- 27.29
- EV to EBITDA
- -27.65
- EV to Free Cash Flow
- -22.76
- EV to Operating Cash Flow
- -23.41
Balance Sheet
Corline Biomedical AB has SEK 32.99M in cash and marketable securities with SEK 0.00 in debt, giving a net cash position of SEK 32.99M billion.
- Cash & Marketable Securities
- SEK 32.99M
- Total Debt
- SEK 0.00
- Net Cash
- SEK 32.99M
- Net Cash Per Share
- SEK 1.26
- Tangible Book Value Per Share
- SEK 0.94
Margins
Gross margin is 39.30%, with operating margin of -97.70%, and net profit margin of -99.48%.
- Gross Margin
- 39.30%
- Operating Margin
- -97.70%
- Pretax Margin
- -99.48%
- Net Profit Margin
- -99.48%
- EBITDA Margin
- -98.71%
- EBIT Margin
- -99.42%
Analyst Forecast
The average price target for Corline Biomedical AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 54.37%
- EPS Growth Forecast
- 52.22%
Scores
- Smart Score
- ―
- AI Score
- 49